Prevalence of Aspirin Resistance in Patients with Transcatheter Pulmonary Valve Replacement
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31440 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Alex Sigman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Roy J. Carver Department of Biomedical Engineering, University of Iowa College of Engineering, Iowa, USA. Hauptthemen laut MEDLINE: Aspirin, Platelet Aggregation Inhibitors, Drug Resistance, Pulmonary Valve. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors thank Patrick Ten Eyck for the statistical analysis of the study data..
Abstract (Originalsprache)
Background
Congenital heart disease (CHD) patients with pulmonary valve failure may undergo transcatheter pulmonary valve replacement (TPVR). Aspirin is often prescribed as long‐term therapy after TPVR to prevent thromboembolic events (TE).
Aims
We aimed to examine the prevalence of aspirin resistance within the CHD TPVR population.
Methods
The VerifyNow point‐of‐care test quantifies platelet aggregation as Aspirin Reactivity Units (ARU). ARU values greater than 550 suggest aspirin resistance (AR). A retrospective chart review analyzed ARU test results from May 2022 through December 2023 in CHD patients following successful TPVR ( n = 48). Lifelong TE history was collected. Association between AR and sex, race, and ethnicity was examined with Fisher's Exact test, and the Wilcoxon rank sum exact test analyzed associations between AR and age.
Results
Three of 45 (6.67%) CHD TPVR aspirin‐compliant patients (average age 33.14 years; range 0.74−77.86 years, 47% females) were AR. Interestingly, all AR patients were females, suggesting higher AR prevalence in females ( p = 0.094). No significant associations were found between AR and age ( p = 0.8), race ( p = 0.077), or ethnicity ( p = 0.2). No AR patients had a documented history of TE. Five of 42 (11.9%) aspirin sensitive patients had TE while taking aspirin, including two females (not on birth control at time of event) and three males.
Conclusions
AR is prevalent in CHD TPVR patients, but TE occurrence did not correlate with AR. However, AR exclusively in females and TE in aspirin sensitive patients, suggests need for further investigations on the most effective TE prophylaxis in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Roy J. Carver Department of Biomedical Engineering, University of Iowa College of Engineering, Iowa, USA.
- Division of Pediatric Cardiology, Department of Pediatrics, University of Iowa Stead Family Children's Hospital, Iowa, USA.
ORCID-Profile: Trudy Pierick, Prashob Porayette
Förderung
- The authors thank Patrick Ten Eyck for the statistical analysis of the study data.
Zitieren
APA
Sigman, A., Riley, E., Pierick, T., Aldoss, O., & Porayette, P. (2025). Prevalence of Aspirin Resistance in Patients with Transcatheter Pulmonary Valve Replacement. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31440
Vancouver
Sigman A, Riley E, Pierick T, Aldoss O, Porayette P. Prevalence of Aspirin Resistance in Patients with Transcatheter Pulmonary Valve Replacement. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31440
BibTeX
@article{Sigman2025,
author = {Sigman, Alex and Riley, Emily and Pierick, Trudy and Aldoss, Osamah and Porayette, Prashob},
title = {Prevalence of Aspirin Resistance in Patients with Transcatheter Pulmonary Valve Replacement},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31440}
}
EUVIMED